Antibody are the glycoprotein structure with immune activity. The production of antibody is ideally using different process and techniques thereby producing, making new antibody based on different foreign antigens. Also, the Antibody production is majorly driven by rising adoption of Monoclonal antibodies in cancer as these antibodies bind to antigen that are generally more numerous on the surface of cancer cells than healthily cells. The developing biotechnology and pharmaceutical manufacturer demand for antibody production from various end user is expected to boost the market growth.
The North America Market in antibody production is majorly driven by increasing R&D expenditure in pharmaceutical and biotechnological companies, as well as number of manufacturer are constantly innovating in antibody production with ongoing clinical trial, rising funding for R&D and new launch in the region for antibody production which is likely to contribute healthily growth in the market. Also, increasing adoption of targeted immunotherapy specifically for cancer treatment will fuel the region’s market growth. Additionally, rising number of fast track and orphan drug designations is the key factor the market growth.
The exclusive COVID 19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the North America antibody production market. In addition, complete analysis of changes on the North America antibody production market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. COVID-19 had a positive impact on market as the demand for the production of new antibody was accelerated specifically for corona viruses.
The antibody production market comprises of different market segment like process, end user, class and geography.
The antibody production includes key process segment of upstream processing, downstream processing, ion exchange (iex) chromatography resins, hydrophobic interaction chromatography (hic) resins, multimodal chromatography resins, and filtration. Further, upstream processing includes bioreactors and consumables. Bioreactors is further sub segmented to large-scale bioreactors and single-use bioreactors (subs). Likewise, consumables includes media and reagents and buffers. Also, downstream processing is bifurcated to chromatography instruments and chromatography resins. Additionally filtration includes filtration systems and filtration consumables and accessories. The downstream processing is expected to register major market growth in North America Antibody Production Market. The growth is due rising demand for antibody production by downstream processing as it provide proper accuracy, and efficient product. In addition, the segment plays significant role in providing products with high standard purity and quality. On the other hand, upstream processing is expected to hold second position in market attributing to its potential to efficiently perform the antibody production which is anticipated to propel the North America in antibody production market.
The antibody production market finds its end use in pharmaceutical and biotechnology companies, diagnostic laboratories and research institutes. In North America market, pharmaceutical and biotechnology companies has gain major market as of rising number of new manufacturer and presence of key players in the region. Besides, growing antibodies production R&D in these segment is the key factor accelerating the growth of region’s market. Also, rising approval for antibody production drugs is likely to contribute in the growth of antibody production market in North America. Likewise, diagnostic laboratories is expected to boost the growth of market during forecast period owing to increasing usage of antibody for microbiology testing of infectious organisms
The antibody production by class is available in market according to monoclonal antibodies, murine, chimeric, humanized and polyclonal antibodies. Monoclonal antibodies is expected to lead in the North America market. The growing of the segment is due to rising demand and adoption of the Monoclonal antibodies specifically in cancer and other disease. Furthermore, ongoing clinical trial for Monoclonal antibodies is fueling the growth of segment thereby driving antibody production market. Also, growing innovation for production and adoption of segment is the key factor the growth of market. Additionally, polyclonal antibodies is expected to contribute healthy growth in market during the forecast period.
North America antibody production market is studied for the following countries like United States, Canada and Mexico. United States is anticipated to dominate in North America Market as the country has the largest production of antibody among other key country. Besides, adoption for the antibody in the region for the treatment of cancer and research is boosting the market demand. Also, presence of key players in region will fuel the market growth to huge extend. Additionally, Canada followed by Mexico is expected to contribute in new growth avenue in North America Antibody Production Market.
The key players in antibody production market are GE Healthcare (General Electric Company), Merck KGAA, Thermo Fisher Scientific, Inc., Sartorius AG, Pall Corporation (Danaher Corporation), Sigma-Aldrich Corporation (Merck KGAA), Eppendorf AG, Cellab GmbH, Integra Biosciences AG and Fibercell Systems Inc. among others.
May 2021: AbCellera had announced the second antibody from its collaboration with Eli Lilly and Company (Lilly), LY-CoV1404 has further entered clinical trials in patient with mild to moderate COVID-19. Also, the Lilly Company had expanded its ongoing BLAZE-4 trials to evaluate LY- CoV1404 alone and together with other monoclonal antibodies.
November 2020: Purolite Ltd had announced that the company will supply its protein A capture resin, Praesto Jetted A50 to WuXi Biologics for immediate use. The WuXi Biologics company will use the Praesto Jetted A50 to provide their customer for affinity chromatography resin for range of downstream processing for monoclonal antibody purification.
September 2020: MilliporeSigma had announced the $65 million expansion of its HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, Wisconsin. The investment will allow the large scale manufacturing of increasingly potent compounds that have potential to treat cancer. The completion is likely to be completed by Mid-2022 and will add approximately 50 full time jobs starting in 2021.
May 2020: AbCellera had announced that the company has received a commitment of up to $175.6 million in support from the Government of Canada under Innovation, Science and Economic Development (ISED) strategic innovation fund to expand the efforts related to discovery of antibodies for use in drugs to treat COVID-19 and build technology and manufacturing infrastructure for antibody therapies.
The report analyses the antibody production market based on by process, end user, class and country. By process, the antibody production includes key segment of upstream processing, downstream processing, ion exchange (iex) chromatography resins, hydrophobic interaction chromatography (hic) resins, multimodal chromatography resins, and filtration. The antibody production market finds its end use in pharmaceutical and biotechnology companies, diagnostic laboratories and research institutes. The antibody production by class is available in market according to monoclonal antibodies, murine, chimeric, humanized and polyclonal antibodies. North America antibody production market is studied for the following countries like United States, Canada and Mexico.
Why to buy this report: